sameAs
The evolution of norovirus, the "gastric flu"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study GroupLate Ebola virus relapse causing meningoencephalitis: a case reportInvariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humansLondon 2012 Olympic and Paralympic Games: public health surveillance and epidemiology.Antivirals in the 2009 pandemic--lessons and implications for future strategies.Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.Current research on respiratory viral infections: Fourth International Symposium.Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemic.A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variantComparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study.Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom.Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy.Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort StudyFast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models.Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.Nucleic acid dipstick test for molecular diagnosis of pandemic H1N1.Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usageEvaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United KingdomImproving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UKOseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010.Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysisAntiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccineVirological self-sampling to monitor influenza antiviral susceptibility in a community cohort.Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.Fatal cases of influenza A(H3N2) in children: insights from whole genome sequence analysis.Programme of the Community Network of Reference Laboratories for Human Influenza to improve Influenza Surveillance in Europe.
P50
Q21090136-87022F38-95F7-43EC-9109-564E6C92DE41Q24604486-C4561AFC-B779-4128-AD57-2C4F2BCAEAAAQ28385572-B2297AC3-788F-46B5-B4A6-355C1DF9C06FQ28511526-D851EA1A-0C82-4A88-9234-645D670338D5Q30210032-3DE5996B-100A-47F8-ABF8-620BFC0EC438Q30219151-540DE934-FB52-49DC-BA84-2342347FA245Q30226427-8D92CB76-42C9-4E50-923D-5EF75B1405D0Q30228084-B449E301-2651-4734-8D7C-C0C43A7E7AC2Q30228322-A25EF5B2-398C-4B1F-B1A2-15DA6B0CCBC3Q30309620-3A2016A4-AF86-40DB-9390-055BB01EF884Q30352644-6CC20630-FD6B-4ABD-A1DA-9A6AB12A5697Q30354814-5A2FFE7B-86C1-462B-A592-154318763B37Q30356990-45A23A4D-7079-4D26-891F-882B2123BDFFQ30360627-1DBA7FEA-94F5-43CE-B56E-16D60C64B09AQ30361230-0F0B695F-ED64-4EB5-9159-3AF39A3E3B52Q30363826-BAF641E8-EBCC-4AA7-9468-E7F4B38F2238Q30366662-559ED34A-2C7D-4919-A01F-9E19F7A855EAQ30367984-D0C70C7C-9AA0-4E6C-AA39-078852EFB5AFQ30369691-1E8AC7CC-1E1C-4FA0-BD0D-F276985A6823Q30373419-9C52974A-5FAA-4B69-8017-994241DBB8D2Q30376757-21C33E45-935C-489B-8FB4-89599DD2EEC4Q30377246-786F55FD-B649-4A92-907E-D69B4647E27DQ30384762-A7A19974-892C-407E-A5E5-920EA9C6BB17Q30391967-A2F3828F-D2A2-463F-944D-BBC4714898ECQ30397620-BBB5AD79-E16F-406E-88C0-CF7A29C2AB47Q30401118-4B3425B5-6D91-4F3B-8706-4DAD20FEC48EQ30402095-5AD635F0-1FAD-4149-B203-D8C9BFA42BE0Q30404708-844B5AEF-6444-406C-A2FA-656E06B85145Q30405696-6A43D596-14E1-4AA5-A589-60EB842CF503Q30406656-EA63F465-4AC6-49BE-818F-EC537B22F1DDQ30408174-4ECA6E70-8DE5-442B-A9A2-9ABDDCAAE81DQ30408425-36021F21-B37B-483F-A933-FBD8501BCC68Q30410899-F5D9F775-4C16-45E3-8237-A6C49B3E11A5Q30425347-039416FC-0345-4752-B047-435C48DDC4A1Q30426674-EA852258-2871-4855-9CC4-1E6470D3869CQ30431823-7490032D-6F09-4A00-AD51-BDE2771D51EBQ30432486-DBCEC146-BE0C-4894-9B1A-B63B091F554CQ30445738-218A7D52-E878-4BC7-BAC5-1B587DB0516BQ31050886-98AE07DE-E7A6-42EE-9057-E737BDD727ECQ33247125-AE6858DA-A21D-494C-9E6C-E656EF10921E
P50
description
British virologist
@en
British virologist
@en-ca
British virologist
@en-gb
viróloga británica
@es
عالمة فيروسات بريطانية
@ar
name
Maria Zambon
@en
type
label
Maria Zambon
@en
prefLabel
Maria Zambon
@en
P106
P21
P31
P496
0000-0002-8897-7881